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Background
•

Lipid lowering has been shown to be beneficial for primary and secondary
prevention of coronary artery disease in patients with dyslipidemias
•

Statin mechanism of action: competitively inhibits HMG CoA reductase (rate limiting step in
cholesterol biosynthesis)

•

Administration of statin therapy guided primarily by risk of CVD

•

Atherosclerotic cardiovascular disease (ASCVD) risk calculation for use only in adult
patients without known ASCVD and LDL 70-189 mg/dL

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. doi: 10.1161/01.cir.0000437741.48606.98.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. doi: 10.1161/01.cir.0000437738.63853.7a.

Robinson G, Stone N. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence.
European Heart Journal, 2015. 36, 2110–2118 doi:10.1093/eurheartj/ehv182.

Robinson G, Stone N. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence.
European Heart Journal, 2015. 36, 2110–2118 doi:10.1093/eurheartj/ehv182.

Study Design
•

Empiric observational study

•

Retrospective chart review of 2,994 patients for information including ASCVD risk
determination and active statin prescription
•

Inclusion Criteria: Adult patients visiting the K15 Academic Internal Medicine Clinic of Henry Ford
Hospital from January 2017- December 2017

•

Primary objective: to assess appropriateness of statin therapy based on ASCVD risk calculation
and ACC/AHA guidelines.

•

Secondary objective: to assess correlation between patient demographic and appropriateness
of statin therapy according to guidelines.

•

Clinical implication: determine proper application of ASCVD guidelines and better improve
patient outcomes in the outpatient setting

Results
1,548 patients were prescribed inappropriate statin dose

- 1,245 patients taking high-intensity statin did not qualify for one based on ASCVD risk

p-value < 0.001

p-value < 0.001

Female patients 81.9% more likely to be on appropriate statin dose vs male patients

OR 1-1.819, 95% CI, 1.559-2.124

Black patients were 32.2% less likely to be on appropriate statin dose vs Caucasian patients

OR 1-0.678, 95% CI, 0.5320-0.864

Patients on appropriate statin dose have a higher family income on average

p-value = 0.020

- Every 10,000-unit increase in income, increases the odds of an appropriate statin dose by 2.4%
For every 1-unit increase in age, the odds of an appropriate statin dose decrease by 4.8%

OR 1-1.024, 95% CI, 0.990-1.060

OR 1-0.952, 95% CI, 0.04-0.056

Limitations
•

•

•

Varying demographics specific to location of Henry Ford Hospital
•

Socioeconomic status

•

Lack of access to healthcare and/or medical insight

Internal validity:
•

Misclassified subgroup: appropriate statin dose misassigned to high

•

Stroke/TIA not considered in risk status determination

Limitations inherent to observational study design
•

May represent older prescribing practices

•

Not fully reflective of current trends

Looking ahead…
•

Treatment according to AHA/ACC guidelines based on ASCVD risk calculation has well documented effect on
morbidity and mortality

•

Appropriate administration of statins by dose and intensity is a necessary intervention aimed at improving
patient outcomes

•

HF pilot program promoting pharmacist-driven initiation and dosing of statins

•

•

Improving adherence

•

Improving administration

•

Improving clinical outcomes

Assessing clinical outcomes in sites with policies in place for initiation and administration of appropriate
dose/intensity statin

Thank you!
Questions?

